SELLAS Life Sciences Group Inc
SLS
Company Profile
Business description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Contact
7 Times Square
Suite 2503
New YorkNY10036
USAT: +1 646 200-5278
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Ask the Analyst: Why are ASX gold miners overvalued despite a near record gold price?
All that glitters is not gold.
stocks
Chart of the Week: Looking past the oil shock to find consumer opportunities
Shoppers are being hit by double whammy of oil and rising rates.
stocks
ASX data center player sells US assets to bolster balance sheet
Asset sale in response to growing investor concerns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,107.00 | 36.90 | 0.41% |
| CAC 40 | 8,299.42 | 237.11 | 2.94% |
| DAX 40 | 24,918.69 | 516.99 | 2.12% |
| Dow JONES (US) | 49,910.59 | 612.34 | 1.24% |
| FTSE 100 | 10,438.66 | 219.55 | 2.15% |
| HKSE | 26,571.17 | 357.39 | 1.36% |
| NASDAQ | 25,838.94 | 512.82 | 2.02% |
| Nikkei 225 | 62,906.05 | 3,392.93 | 5.70% |
| NZX 50 Index | 13,270.61 | 125.42 | 0.95% |
| S&P 500 | 7,365.12 | 105.90 | 1.46% |
| S&P/ASX 200 | 8,878.10 | 32.70 | 0.37% |
| SSE Composite Index | 4,174.98 | 14.81 | 0.36% |